Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$15.68 USD
-0.10 (-0.63%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $15.69 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
MYGN 15.68 -0.10(-0.63%)
Will MYGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYGN
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Other News for MYGN
Myriad Genetics price target lowered to $24 from $34 at Scotiabank
Myriad Genetics price target lowered by $10 at Scotiabank, here's why
Myriad Genetics expands access to at-home early fetal sex DNA test
Myriad Genetics expands access to at-home early fetal sex DNA test
Myriad Genetics (MYGN) Gets a Buy from Scotiabank